-+ 0.00%
-+ 0.00%
-+ 0.00%

Analysts Have Lowered Expectations For Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) After Its Latest Results

Simply Wall St·11/15/2026 12:41:25
Listen to the news

It's shaping up to be a tough period for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), which a week ago released some disappointing annual results that could have a notable impact on how the market views the stock. Revenues missed expectations somewhat, coming in at US$451m, but statutory earnings fell catastrophically short, with a loss of US$5.11 some 42% larger than what the analysts had predicted. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

earnings-and-revenue-growth
NasdaqGS:ARWR Earnings and Revenue Growth November 15th 2026

After the latest results, the consensus from Arrowhead Pharmaceuticals' eleven analysts is for revenues of US$306.6m in 2027, which would reflect a painful 32% decline in revenue compared to the last year of performance. Losses are expected to increase slightly, to US$5.53 per share. Before this earnings announcement, the analysts had been modelling revenues of US$328.2m and losses of US$4.69 per share in 2027. So it's pretty clear the analysts have mixed opinions on Arrowhead Pharmaceuticals after this update; revenues were downgraded and per-share losses expected to increase.

See our latest analysis for Arrowhead Pharmaceuticals

The average price target was broadly unchanged at US$106, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Arrowhead Pharmaceuticals analyst has a price target of US$126 per share, while the most pessimistic values it at US$73.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that revenue is expected to reverse, with a forecast 32% annualised decline to the end of 2027. That is a notable change from historical growth of 33% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 21% annually for the foreseeable future. It's pretty clear that Arrowhead Pharmaceuticals' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. The consensus price target held steady at US$106, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Arrowhead Pharmaceuticals going out to 2029, and you can see them free on our platform here..

You should always think about risks though. Case in point, we've spotted 2 warning signs for Arrowhead Pharmaceuticals you should be aware of.